NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages

  Zhang, Yan ^a   Fan, Yudong ^b   Mei, Zhechuan ^c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathology; Hepatocellular carcinoma; NGAL; NGALR; Prognosis

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOCALINS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANIC CATION TRANSPORT PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865862439     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.05.012     Document Type: Article

References (28)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J Clin 2005, 55:74-108.
3. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127:S218-S224.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
5. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
6. Rodvold J.J., Mahadevan N.R., Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett 2012, 316:132-138.
7. Li C., Chan Y.R. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine 2011, 56:435-441.
8. Jin D., Zhang Y., Chen X. Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells. Mol Cell Biochem 2011, 351:165-172.
9. Wang P.H., Yang S.F., Tseng C.J., Ying T.H., Ko J.L., Lin L.Y. The role of lipocalin 2 and its concernment with human nonmetastatic clone 23 type 1 and p53 in carcinogenesis of uterine cervix. Reprod Sci 2011, 18:447-455.
10. Leng X., Wu Y., Arlinghaus R.B. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 2011, 226:309-314.
11. Lin H.H., Liao C.J., Lee Y.C., Hu K.H., Meng H.W., Chu S.T. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci 2011, 7:74-86.
12. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007, 120:2426-2434.
13. Furutani M., Arii S., Mizumoto M., Kato M., Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett 1998, 122:209-214.
14. Kubben F.J., Sier C.F., Hawinkels L.J., Tschesche H., van Duijn W., Zuidwijk K., et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007, 43:1869-1876.
15. Barresi V., Vitarelli E., Reggiani Bonetti L., Tuccari G., Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. Virchows Arch 2012, 460:319-325.
16. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10:1033-1043.
17. Du Z.P., Lv Z., Wu B.L., Wu Z.Y., Shen J.H., Wu J.Y., et al. Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinoma. J Clin Pathol 2011, 64:69-74.
18. Liu M.F., Jin T., Shen J.H., Shen Z.Y., Zheng Z.C., Zhang Z.L., et al. NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis. J Neurooncol 2011, 104:119-127.
19. Patil M.A., Chua M.S., Pan K.H., Lin R., Lih C.J., Cheung S.T., et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005, 24:3737-3747.
20. Lee E.K., Kim H.J., Lee K.J., Lee H.J., Lee J.S., Kim D.G., et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol 2011, 38:325-333.
21. Giasson J., Li G.H., Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets 2011, 10:272-282.
22. Mir S.U., Jin L., Craven R.J. Neutrophil gelatinase-associated lipocalin (NGAL) expression dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem 2012, 287:14494-14501.
23. Yang J., Moses M.A. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009, 8:2347-2352.
24. Moniaux N., Chakraborty S., Yalniz M., Gonzalez J., Shostrom V.K., Standop J., et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008, 98:1540-1547.
25. Tong Z., Wu X., Ovcharenko D., Zhu J., Chen C.S., Kehrer J.P. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005, 391:441-448.
26. Lee H.J., Lee E.K., Lee K.J., Hong S.W., Yoon Y., Kim J.S. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 2006, 118:2490-2497.
27. Hu L., Hittelman W., Lu T., Ji P., Arlinghaus R., Shmulevich I., et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009, 89:531-548.
28. Nuntagowat C., Leelawat K., Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis 2010, 27:295-305.